Sobi Advances Growth Strategy With Gamifant Launch In Early 2019 For Primary HLH

The interferon gamma blocker is the first new therapy for HLH in 24 years. FDA approval came about four months after Sobi acquired global rights from NovImmune in a deal meant to improve the company's growth prospects.